MX2021011030A - Formulacion solida del modulador de ensamblaje de la capside. - Google Patents

Formulacion solida del modulador de ensamblaje de la capside.

Info

Publication number
MX2021011030A
MX2021011030A MX2021011030A MX2021011030A MX2021011030A MX 2021011030 A MX2021011030 A MX 2021011030A MX 2021011030 A MX2021011030 A MX 2021011030A MX 2021011030 A MX2021011030 A MX 2021011030A MX 2021011030 A MX2021011030 A MX 2021011030A
Authority
MX
Mexico
Prior art keywords
capsid assembly
solid formulation
assembly modulator
modulator
capsid
Prior art date
Application number
MX2021011030A
Other languages
English (en)
Inventor
Oliver Lenz
Claire Elisabeth Balmain
Jan Snoeys
Joris Jozef Vandenbossche
Dominique Josiane W Verstraete
Maria Jansens
Michaël Bertil S Anné
Abhishek Singh
Van Dycke Frederic Anne R
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/352,754 external-priority patent/US10973801B2/en
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MX2021011030A publication Critical patent/MX2021011030A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente divulgación se refiere a formas farmacéuticas orales sólidas un inhibidor de ensamblaje de la cápside para el tratamiento de la infección por el virus de la hepatitis B.
MX2021011030A 2019-03-13 2020-03-13 Formulacion solida del modulador de ensamblaje de la capside. MX2021011030A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16/352,754 US10973801B2 (en) 2018-03-14 2019-03-13 Capsid assembly modulator dosing regimen
PCT/IB2019/000231 WO2019175657A1 (en) 2018-03-14 2019-03-13 Capsid assembly modulator dosing regimen
EP2019056348 2019-03-13
EP19197566 2019-09-16
PCT/EP2020/056991 WO2020183020A1 (en) 2019-03-13 2020-03-13 Capsid assembly modulator solid formulation

Publications (1)

Publication Number Publication Date
MX2021011030A true MX2021011030A (es) 2021-10-13

Family

ID=72427202

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011030A MX2021011030A (es) 2019-03-13 2020-03-13 Formulacion solida del modulador de ensamblaje de la capside.

Country Status (16)

Country Link
EP (1) EP3937928A1 (es)
JP (1) JP2022524819A (es)
KR (1) KR20210137484A (es)
CN (1) CN113557016A (es)
AU (1) AU2020235442A1 (es)
BR (1) BR112021017525A2 (es)
CA (1) CA3132095A1 (es)
CR (1) CR20210481A (es)
EC (1) ECSP21067052A (es)
IL (1) IL286209A (es)
JO (1) JOP20210250A1 (es)
MA (1) MA55280A (es)
MX (1) MX2021011030A (es)
PE (1) PE20212107A1 (es)
SG (1) SG11202109710QA (es)
WO (1) WO2020183020A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3848026A1 (en) 2016-04-15 2021-07-14 Novira Therapeutics Inc. Combinations and methods comprising a capsid assembly inhibitor
MA52019A (fr) * 2018-03-14 2021-01-20 Janssen Sciences Ireland Unlimited Co Schéma posologique de modulateur d'assemblage de capside

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
MA52019A (fr) * 2018-03-14 2021-01-20 Janssen Sciences Ireland Unlimited Co Schéma posologique de modulateur d'assemblage de capside

Also Published As

Publication number Publication date
CR20210481A (es) 2021-10-25
JP2022524819A (ja) 2022-05-10
SG11202109710QA (en) 2021-10-28
CA3132095A1 (en) 2020-09-17
EP3937928A1 (en) 2022-01-19
KR20210137484A (ko) 2021-11-17
BR112021017525A2 (pt) 2021-11-23
IL286209A (en) 2021-10-31
WO2020183020A1 (en) 2020-09-17
JOP20210250A1 (ar) 2023-01-30
AU2020235442A1 (en) 2021-08-12
ECSP21067052A (es) 2021-11-18
MA55280A (fr) 2022-01-19
PE20212107A1 (es) 2021-11-04
CN113557016A (zh) 2021-10-26

Similar Documents

Publication Publication Date Title
PH12020551421A1 (en) Capsid assembly modulator dosing regimen
JOP20180123A1 (ar) مركبات علاجية مفيدة للوقاية من أو علاج الإصابة بفيروس نقص المناعة البشرية
MX2020011808A (es) Combinaciones y metodos que comprenden un inhibidor del ensamblaje de la capside.
PH12016501631A1 (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
EA201892034A1 (ru) Элиминация вируса гепатита в при помощи противовирусных агентов
MX2018005230A (es) Terapia de combinacion de un inhibidor del ensamble de la capside del hbv y un interferon.
GEP20146134B (en) Inhibitors of hepatitis c virus replication
EA201890200A1 (ru) Производные циклизированного сульфамоилариламида и их применение в качестве лекарственных препаратов для лечения гепатита b
EA201591220A1 (ru) Новые противовирусные агенты против инфекции вирусом гепатита в
MX2022009352A (es) Sal de hemisulfato de nucleotido para el tratamiento del virus de hepatitis c.
EA201890654A1 (ru) Терапевтические композиции для лечения вируса иммунодефицита человека
NZ739248A (en) Inhibitors of hepatitis c virus
MX2021011030A (es) Formulacion solida del modulador de ensamblaje de la capside.
EA202190854A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
JOP20190214A1 (ar) ثنائي هيدرو إيندين-?-كربوكساميدات ونظائر منها بها استبدال، وطرق تستخدمها
MX2022007909A (es) Combinacion farmaceutica de agentes antivirales que actuan sobre hbv y/o un inmunomodulador para el tratamiento de hbv.
MX2019009659A (es) Dosis mejorada de baloxavir marboxil para pacientes pediatricos.
EA202192967A1 (ru) Новые индол-2-карбоксамиды, активные против вируса гепатита b (вгв)
EA202191109A1 (ru) Соединения 5-членного гетероарилкарбоксамида для лечения вируса гепатита в
MX2021016022A (es) Efecto sinergico de eyp001 e ifn para el tratamiento de la infeccion por hbv.
MX2019015236A (es) Uso de la rpobenecida y sus derivados como inhibidores de la neuraminidasa del virus de la influenza.
EA201892348A1 (ru) Комбинации и способы, включающие ингибитор сборки капсида
PH12015502258A1 (en) Solid oral dosage formulation of hcv inhibitor in the amorphous state